The research, conducted at Hospital Alberto Barton Thompson in Callao and published in Frontiers in Nephrology, set out to answer a deceptively simple question: when a bedside exam, a bioimpedance scan, and a lung ultrasound are all performed on the same patient on the same morning, do they agree? The answer, quantified with statistical rigor, was largely no. The three methods captured overlapping but partially distinct slices of a patient’s true fluid status, and the disagreements were not random noise but appeared to reflect genuinely different physiology.

The technical centerpiece of the study is the B-line, a vertical, laser-like reverberation artifact that streaks down an ultrasound image from the pleural line and moves in synchrony with lung sliding. B-lines increase when fluid accumulates in the interlobular septa and alveoli of the lung, making their count a practical surrogate for extravascular lung water. The team used an abbreviated six-zone protocol, scanning two intercostal spaces along the midclavicular line and one along the midaxillary line on each side, a compromise that previous validation work has shown performs comparably to the traditional 28-zone survey while cutting acquisition time dramatically. Two formally trained nephrologists performed all scans with a handheld Butterfly iQ+ device, blinded to every other clinical and bioimpedance finding, and adjudicated disagreements by consensus.

Alongside the ultrasound, each patient underwent whole-body bioimpedance spectroscopy using a Fresenius Body Composition Monitor, which estimates how many liters of excess extracellular fluid a person carries relative to their normohydrated state. The investigators also performed a standardized clinical examination, recording dyspnea, crackles, peripheral edema, blood pressure, and interdialytic weight gain, and defined clinical euvolemia as the absence of all congestion signs. All measurements were taken immediately before the same midweek dialysis session, eliminating the temporal drift that has muddied earlier comparisons.

The headline result is striking. Of the 49 patients judged clinically euvolemic, 27, or 55.1 percent, had three or more B-lines on lung ultrasound, meeting the prespecified definition of subclinical pulmonary congestion. That subgroup alone constituted 23.3 percent of the entire cohort. In other words, nearly one in four dialysis patients in this study was walking around with objectively wet lungs despite a clean physical examination, no edema, and no crackles. Overall, 70.7 percent of participants had ultrasound-defined pulmonary congestion, and 41.4 percent had moderate-to-severe congestion with ten or more B-lines.

Agreement statistics drove the point home. Clinical examination showed only fair agreement with lung ultrasound at the three-B-line threshold, with a Cohen’s kappa of 0.28, improving to a still-modest 0.41 at the ten-B-line cutoff. Agreement between lung ultrasound and bioimpedance-defined overhydration was slight, at kappa 0.16, and the ultrasound agreed barely at all with elevated interdialytic weight gain, at kappa 0.08. Even the two objective technologies, which might naively be expected to converge, classified the same patients differently. The authors argue this physiological discordance is the story itself: fluid overload describes expansion of the body’s extracellular compartment, whereas congestion describes where that fluid actually accumulates and redistributes, and the two do not move in lockstep.

By combining clinical and ultrasound findings, the team carved the cohort into four volume phenotypes. Twenty-two patients were concordantly euvolemic, 55 were concordantly congested, 12 showed clinical signs without ultrasound congestion, and 27 occupied the discordant zone of subclinical pulmonary congestion. The phenotypes sorted cleanly along physiological gradients: concordantly congested patients had the highest weight gain, the greatest bioimpedance overhydration, and the heaviest B-line burden, while concordantly euvolemic patients sat at the bottom of every measure. The subclinical group fell in between, with intermediate overhydration that a stethoscope simply could not see.

Regression analysis sharpened the clinical message. Among euvolemic patients, each additional liter of bioimpedance-derived overhydration was associated with a 24 percent higher prevalence of subclinical pulmonary congestion, while interdialytic weight gain, the traditional dialysis-unit benchmark, lost all statistical significance after adjustment. Male sex was independently associated with a 45 percent lower prevalence of occult congestion. Blood pressure told a similarly bifurcated tale: systolic pressure correlated moderately with systemic overhydration but not with B-lines, whereas diastolic pressure showed only a weak link to lung water. These patterns reinforce the idea that whole-body fluid volume, weight fluctuation, and pulmonary congestion are separable physiological dimensions rather than interchangeable labels.

The findings resonate with a growing international literature. Meta-analyses report pulmonary congestion in roughly one half to two thirds of maintenance hemodialysis patients worldwide, and the landmark LUST study found that pulmonary crackles, the classic auscultatory sign, detected significant congestion with a sensitivity of only about 22 percent. Studies from Asia and Europe have likewise shown that patients deemed normohydrated by bioimpedance frequently carry ultrasound-visible lung water. The Peruvian cohort, notable as one of the first Latin American populations examined with this triple assessment, adds weight to the argument that clinically silent congestion is a reproducible global phenomenon rather than a local artifact.

What the study cannot yet say is whether acting on this hidden information saves lives. Its cross-sectional design precludes causal inference, it came from a single center where most patients dialyzed through central venous catheters, and echocardiography was available for only about half the cohort. The three-B-line threshold for subclinical congestion was prespecified but not universally validated, though sensitivity analyses at five and ten B-lines produced similar patterns. Still, the clinical direction is clear. The authors do not propose replacing the hands and stethoscope of conventional assessment, but they make a strong case for layering lung ultrasound and bioimpedance on top of it when fluid status is uncertain. With randomized trials of ultrasound-guided fluid management already underway, the era in which a wet lung could hide in plain sight on a dialysis chair may soon be ending.

Subject of Research: Discordance among clinical examination, bioimpedance spectroscopy, and lung ultrasound for assessing fluid status and pulmonary congestion in maintenance hemodialysis patients

Article Title: Physiological discordance between clinical examination, bioimpedance spectroscopy, and lung ultrasound in maintenance hemodialysis patients without heart failure

Article References: Benites-Flores, I. R., Rodríguez Revilla, J., Taype-Rondan, A., Fernández-Anticona, L. C., Prado Ramírez, P. A., Seminario Alegre, N., Rodríguez Tudero, C., Moral Berrio, E., Jimenez Mayor, E., Chandu Nanwani, A., & De la Flor, J. C. (2026). Physiological discordance between clinical examination, bioimpedance spectroscopy, and lung ultrasound in maintenance hemodialysis patients without heart failure. Frontiers in Nephrology, 6, Article 2000700. https://doi.org/10.3389/fneph.2026.2000700

Image Credits: AI Generated

DOI: 10.3389/fneph.2026.2000700

Keywords: hemodialysis, lung ultrasound, bioimpedance spectroscopy, pulmonary congestion, B-lines, volume assessment, fluid overload, point-of-care ultrasound, nephrology, subclinical congestion, dry weight, cardiovascular risk

The study, published in Supportive Care in Cancer by a research team led by Jinting Sun and colleagues at the First Affiliated Hospital of Soochow University in Suzhou, set out to understand why early screening behavior for BCRL varies so widely among survivors. Rather than measuring screening rates numerically, the researchers took a qualitative descriptive approach, conducting semi-structured interviews with 20 postoperative breast cancer patients recruited from a tertiary hospital. They used purposive sampling with maximum variation to ensure the participants reflected a range of ages, treatment experiences, and backgrounds, and they analyzed the transcripts using the six-phase thematic analysis procedure developed by Braun and Clarke, with reporting that followed the COREQ guidelines for qualitative research. The goal was not to count barriers but to understand them from the inside, through the words and reasoning of the patients themselves.

To organize their inquiry, the team anchored the study in the health belief model, a classic framework in health psychology first articulated in the 1950s and later refined by Janz and Becker. The model proposes that whether a person adopts a preventive health behavior depends on several cognitive appraisals: their perceived susceptibility to the condition, their perception of its severity, their belief in the benefits of taking action, their assessment of the barriers to action, and the internal cues and self-efficacy that drive them to act. Applied to BCRL, the model asks a deceptively simple question: if screening can prevent a debilitating complication, why do so many survivors not show up for it? The answers that emerged from the Suzhou interviews were layered and, in places, unexpected.

The first major theme the researchers identified was limited understanding and misinterpretation of BCRL risk. Many participants simply did not know what lymphedema was, had never heard the term before their surgery, or confused it with ordinary postoperative swelling that resolves on its own. Some underestimated their personal risk, assuming that lymphedema was something that happened to other people, or that their own treatment had been mild enough to spare them. This pattern of unrealistic optimism is well documented in the screening literature; earlier work on Israeli women’s screening intentions by Barnoy and colleagues showed how perceived control and optimism can suppress preventive behavior. In the Suzhou cohort, limited awareness of the long-term consequences of lymphedema—including its chronicity, its cosmetic and functional impact, and its links to psychological distress and even sleep problems—further weakened any sense of urgency. When a threat feels vague and distant, the cognitive machinery that motivates prevention rarely engages.

The second theme captured the motivations and barriers to screening behavior themselves. Participants who did attend screening often did so because they perceived concrete benefits: the possibility of catching swelling early, receiving timely guidance on arm care, and avoiding the heavier costs of late-stage treatment. But these perceived benefits competed against a formidable array of barriers. Some patients expressed skepticism about whether screening actually worked or whether early detection changed outcomes at all. Others described logistical hurdles—travel time, appointment scheduling, out-of-pocket costs, and the sheer fatigue of recovering from cancer treatment while juggling family and work obligations. The health belief model predicts exactly this tension: behavior emerges only when perceived benefits outweigh perceived barriers, and for many survivors in this study, the balance tipped away from screening.

The third theme broadened the lens from individual cognition to social and systemic constraints. Screening behavior, the interviews made clear, does not happen in a vacuum. Participants described family dynamics that shaped whether they could prioritize their own follow-up care, with some women deprioritizing their health in favor of caregiving responsibilities. They also pointed to gaps in the healthcare system itself: limited survivorship follow-up structures, inconsistent communication from clinicians about lymphedema risk, and scarce access to specialized screening services such as bioimpedance spectroscopy, which clinical practice guidelines, including the 2024 MASCC international Delphi consensus recommendations, identify as a valuable tool for detecting subclinical lymphedema. This systemic dimension echoes broader findings in the literature; a 2025 systematic review by Mattia and colleagues documented persistent inequities and barriers in lymphedema care, and a 2024 study in a safety-net hospital by Young and colleagues found substantial screening and treatment gaps even within well-resourced health systems.

The fourth and perhaps most hopeful theme concerned self-efficacy and health responsibility. Even among patients facing real obstacles, some had internalized a sense of ownership over their long-term health. These participants described screening not as an imposition but as an expression of responsibility to themselves and their families, and they reported confidence in their ability to carry out the recommended behaviors. This aligns with cross-sectional evidence from Chinese women showing that self-efficacy mediates the relationship between social support and cancer screening behavior, as reported by Tu and colleagues in 2024. In the health belief model’s terms, self-efficacy functions as the engine that converts awareness into action; without it, even well-informed patients may stall. The Suzhou findings suggest that cultivating this internalized health responsibility may be as important as delivering information.

Taken together, the four themes paint a picture of screening behavior as an interaction between cognitive appraisal, contextual constraints, and health system factors. No single lever—patient education alone, or clinic access alone—will move the needle. The authors conclude that interventions should focus on strengthening survivorship follow-up, improving clinician communication about lymphedema risk, and expanding access to screening services. In practical terms, this could mean embedding lymphedema education into routine postoperative consultations, providing clear risk information tailored to each patient’s treatment profile, and building screening into standard follow-up pathways rather than leaving it as an optional extra that patients must seek out on their own initiative.

The stakes are considerable. Breast cancer remains the most commonly diagnosed cancer among women globally, with GLOBOCAN 2022 estimates documenting its enormous and growing burden. As survival improves, the population living with treatment sequelae expands in parallel, and the cumulative economic burden of lymphedema treatment—documented in a systematic review by De Vrieze and colleagues—is substantial for both patients and health systems. Risk prediction models for BCRL, reviewed by Lin and colleagues, are becoming more sophisticated, and diagnostic tools such as bioimpedance spectroscopy now have dedicated clinical practice guidelines. The science of detection is advancing; the science of getting patients through the door is lagging behind, and this study helps explain why.

What makes the Suzhou study valuable is precisely its refusal to treat non-screening as simple negligence. The interviews reveal rational patients making decisions within constrained circumstances, shaped by incomplete information, competing priorities, skepticism, and system-level friction. For clinicians, the message is that communication must do more than inform; it must build perceived susceptibility without inducing fatalism, demonstrate the tangible benefits of early detection, and lower the practical barriers that stand between intention and action. For policymakers, the message is that survivorship care pathways need structural reinforcement so that screening becomes the default rather than the exception. And for survivors themselves, the study is a reminder that a feeling of well-being in the months after surgery is not a guarantee of freedom from lymphedema, and that a simple, early check may be one of the most consequential health decisions of the survivorship journey.

Subject of Research: Factors influencing early screening behavior for breast cancer–related lymphedema among postoperative breast cancer patients, analyzed through the health belief model

Article Title: Based on the health belief model: a qualitative exploration of factors influencing early screening behavior for breast cancer–related lymphedema

Article References: Sun, J., Chen, Y., Xu, J., Jiang, Y., & Ji, J. (2026). Based on the health belief model: a qualitative exploration of factors influencing early screening behavior for breast cancer–related lymphedema. Supportive Care in Cancer, 34(10), Article 974. https://doi.org/10.1007/s00520-026-11219-3

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11219-3

Keywords: breast cancer-related lymphedema, screening behavior, health belief model, qualitative research, self-efficacy, cancer survivors, perceived susceptibility, health barriers, survivorship care, bioimpedance spectroscopy, patient education, China

The data came from the Australian Lymphedema Education, Research and Treatment (ALERT) Centre Databank at Macquarie University in Sydney. The researchers extracted records from 282 female patients with confirmed BCRL, covering 289 affected limbs, including seven patients with lymphedema on both sides. Each patient had undergone indocyanine green (ICG) lymphography, an imaging technique in which a fluorescent tracer is injected into the skin and visualized with a near-infrared camera. During these sessions, four trained clinicians drew the observed lymphatic drainage pathways directly onto paper templates of the patient’s arm, marking regions of dermal backflow in red once the signal stabilized after roughly an hour. These annotated summary diagrams, digitized as high-resolution images, became the raw material for the atlas. Alongside the images, the databank provided rich clinical information: age, duration of lymphedema, cancer treatment history, limb volume difference, bioimpedance spectroscopy scores known as L-Dex, body mass index, and the clinician-assigned MD Anderson Cancer Center (MDACC) stage of lymphedema severity.

Turning hand-drawn diagrams from hundreds of patients into a single coherent map posed a genuine computational challenge. The team chose a left-arm template as the reference space and horizontally flipped diagrams from right-sided cases, an approach justified by the known symmetry of normal upper-limb lymphatic drainage when assessed by nodal basin. Each diagram was then aligned to the template using feature-based image co-registration: the ORB algorithm, which combines the FAST keypoint detector with the BRIEF descriptor, identified matching landmarks, while the RANSAC algorithm estimated the geometric transformation needed to overlay every image onto the common frame. Segmentation of the red dermal backflow regions was performed semi-automatically by thresholding in the CIELAB perceptual color space, exploiting the fact that the A-channel captures the green-red axis of an image. Morphological operations cleaned up small artifacts, and the researchers manually corrected masks where necessary using image editing software before quality checks.

Once every diagram was registered and segmented, the binary masks, marking background as zero and dermal backflow as one, were stacked into a three-dimensional volume with one slice per patient study. A pixel-wise mean across the stack produced a frequency map: for every anatomical location on the arm, the proportion of patients exhibiting dermal backflow at that spot. The result is, in effect, a probabilistic heat map of lymphatic failure painted onto the anatomy of the upper limb. The team also generated subgroup-specific heat maps stratified by MDACC stage, L-Dex ratio, limb volume difference, lymphatic drainage region, and the presence of backflow in the hand, allowing them to see how the geography of disease shifts as severity increases.

The atlas revealed striking and reproducible spatial patterns. In the anterior view, dermal backflow reached its highest prevalence, up to roughly 80 percent, in the medial wrist and forearm, then faded progressively toward the elbow and upper arm. In the posterior view, prevalence climbed even higher, approaching 90 percent in the olecranon region and forearm. By contrast, the fingers, the shoulder, and, notably, the region near the axilla showed the lowest frequencies, below 10 percent. The thenar eminence at the base of the thumb was the most commonly affected part of the hand. This distal-to-proximal gradient suggests that lymphatic dysfunction in BCRL is not a diffuse, uniform process but a regionally patterned one, with certain anatomical zones acting as consistent hotspots of failure across hundreds of individuals.

The subgroup analyses added clinical depth. As MDACC stage increased from 1 to 4, dermal backflow became more extensive and spread more proximally up the limb. Higher L-Dex ratios and greater limb volume differences were likewise associated with broader regions of involvement. Patients whose lymph drained through alternative routes beyond the predominant ipsilateral axilla showed distinct patterns, and those with hand involvement displayed more distally concentrated backflow with less upper-arm involvement. Perhaps most clinically provocative, dermal backflow was frequently observed in limbs with minimal or even negative limb volume difference, hinting that lymphatic dysfunction can precede measurable swelling. Because negative volume differences can arise from arm dominance and baseline variability, the finding underscores a key limitation of conventional volume- and impedance-based assessments: they may underestimate early or spatially localized disease that a spatial heat map can capture as a continuous probability signal.

Why the forearm and wrist should be so vulnerable remains an open question, but the authors point to the underlying organization of upper-extremity lymphatic drainage and the lymphosome concept, which divides the body into discrete lymphatic territories. The antecubital region is associated with drainage toward the epitrochlear nodes en route to the axilla, while the low prevalence near the axilla itself may simply reflect the normal convergence of superficial lymphatics into deeper nodal structures as they approach their destination. The patterns also echo earlier physiological work: a study by Mayrovitz and colleagues reported regional variability in superficial tissue water content in women treated for breast cancer even before overt lymphedema appeared. The new atlas suggests that this regional susceptibility is preserved, and possibly amplified, in established disease, with distal regions showing roughly 70 percent prevalence compared with about 30 percent proximally.

The second half of the study translated these imaging insights into prediction. Using Spearman’s rank correlation, the team narrowed 28 clinical variables down to 13 statistically significant and clinically relevant features. Dermal backflow percentage, calculated as the segmented backflow area divided by the total upper-limb area across anterior and posterior views, showed the strongest correlation with MDACC stage at rho equals 0.90, far exceeding L-Dex at 0.67 and limb volume difference at 0.65. Five machine learning models were then trained to classify stage: multinomial logistic regression, random forest, multi-layer perceptron, k-nearest neighbors, and support vector machine, evaluated with five-fold stratified cross-validation under a one-versus-rest framework.

The results were clear. When dermal backflow percentage was included, random forest achieved the highest area under the curve at 0.94 with precision of 0.768, while multinomial logistic regression posted the best F1 score at 0.926 and sensitivity of 0.735, both with accuracy around 0.737 and specificity above 0.92. The neural network and support vector machine performed at an intermediate level, and k-nearest neighbors lagged throughout. Critically, removing dermal backflow from the feature set degraded every model, with random forest’s AUC falling to 0.832. The authors note that the simpler, interpretable models outperforming deep architectures is good news for clinical translation, where understanding why a model assigns a stage matters as much as the assignment itself. Interestingly, the non-linear models showed higher sensitivity for advanced stage 4 disease, though by that point lymphedema is typically clinically obvious anyway.

The study has limitations the authors acknowledge candidly. The atlas reflects clinician interpretation of ICG studies rather than raw imaging data, and although standardized training reduced variability among the four annotators, differences in interpretation may have influenced the maps. A U-Net deep learning segmentation model was trialed to automate the pipeline but degraded on the full dataset, particularly in the small and variable hand regions, so manual correction remained necessary. The two-dimensional diagrams also approximate, rather than perfectly capture, the curved three-dimensional skin surface. Still, the framework opens concrete paths forward: external validation in multi-centre cohorts, fully automated registration and segmentation, three-dimensional volumetric analysis, and investigation of whether sentinel versus axillary lymph node dissection produce different backflow patterns. For now, the atlas offers clinicians a reference for what typical lymphatic failure looks like across a large cohort, and a quantitative, reproducible measure of severity that could complement, rather than replace, existing assessment, potentially catching the disease before the tape measure can.

Subject of Research: Spatial mapping of dermal backflow and machine learning-based staging of breast cancer-related lymphedema

Article Title: A dermal backflow atlas of lymphatic dysfunction in breast cancer-related lymphedema with machine learning-based stage prediction

Article References: Sutejitsiri, L., Suami, H., Nielsen, P. M. F., Phillips, A. R. J., & Reynolds, H. M. (2026). A dermal backflow atlas of lymphatic dysfunction in breast cancer-related lymphedema with machine learning-based stage prediction. Breast Cancer Research and Treatment, 219(3), Article 28. https://doi.org/10.1007/s10549-026-08093-2

Image Credits: AI Generated

DOI: 10.1007/s10549-026-08093-2

Keywords: breast cancer-related lymphedema, dermal backflow, ICG lymphography, machine learning, spatial atlas, MDACC staging, lymphatic drainage, random forest, bioimpedance spectroscopy, upper limb, image segmentation, early detection